Integra LifeSciences (NASDAQ: IART) reported Q2 EPS of $0.33, $0.23 better than the analyst estimate of $0.10. Revenue for the quarter came in at $258.7 million versus the consensus estimate of $242.8 million.

The Company's full-year 2020 guidance remains withdrawn due to the uncertainty related to COVID-19 and the extent of the recovery in surgical procedure volumes.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.